NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free CMND Stock Alerts $1.16 -0.04 (-3.33%) (As of 04:27 PM ET) Add Compare Share Share Today's Range$1.15▼$1.2050-Day Range$1.08▼$1.8852-Week Range$0.92▼$23.70Volume22,980 shsAverage Volume1.30 million shsMarket Capitalization$1.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Clearmind Medicine alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Clearmind Medicine Stock (NASDAQ:CMND)Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Read More CMND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMND Stock News HeadlinesApril 17, 2024 | msn.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 17, 2024 | globenewswire.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 11, 2024 | uk.investing.comClearmind Medicine advances trial for alcohol use disorder treatmentApril 10, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 9, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 9, 2024 | globenewswire.comClearmind Medicine CEO Issues Letter to ShareholdersMarch 29, 2024 | uk.investing.comClearmind Medicine files tenth patent for depression treatmentMarch 27, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | globenewswire.comClearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 19, 2024 | globenewswire.comBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | msn.comClearmind Medicine receives nod for delisting of shares from Canadian Securities ExchangeMarch 13, 2024 | globenewswire.comClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | globenewswire.comClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 12, 2024 | msn.comPodcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive BehaviorsFebruary 27, 2024 | msn.comEXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine CompoundsFebruary 27, 2024 | globenewswire.comClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsFebruary 23, 2024 | globenewswire.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderFebruary 22, 2024 | benzinga.comClearmind Medicine Stock (NASDAQ:CMND), Quotes and News SummaryFebruary 21, 2024 | benzinga.comNext-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 PatentsFebruary 20, 2024 | msn.comWhat's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?See More Headlines Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/26/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMND CUSIPN/A CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-265.38% Return on Assets-121.95% Debt Debt-to-Equity Ratio0.01 Current Ratio1.96 Quick Ratio1.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book0.27Miscellaneous Outstanding Shares1,690,000Free FloatN/AMarket Cap$1.96 million OptionableNot Optionable Beta1.69 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Adi Zuloff-Shani Ph.D. (Age 55)Chief Executive Officer Prof. Mark Haden (Age 69)Vice President of Business Development Mr. Gilad BabchukHead of Strategy & CommunicationKey CompetitorsQualigen TherapeuticsNASDAQ:QLGNSalarius PharmaceuticalsNASDAQ:SLRXNotable LabsNASDAQ:NTBLLucy Scientific DiscoveryNASDAQ:LSDIBio-PathNASDAQ:BPTHView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCSold 30,564 shares on 2/14/2024Ownership: 5.485%View All Institutional Transactions CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed in 2024? Clearmind Medicine's stock was trading at $2.81 at the start of the year. Since then, CMND stock has decreased by 58.7% and is now trading at $1.16. View the best growth stocks for 2024 here. Are investors shorting Clearmind Medicine? Clearmind Medicine saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 160,200 shares, a decline of 10.4% from the March 31st total of 178,800 shares. Based on an average daily trading volume, of 741,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 5.5% of the company's shares are short sold. View Clearmind Medicine's Short Interest. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) released its earnings results on Monday, March, 18th. The company reported ($0.90) earnings per share for the quarter. What ETF holds Clearmind Medicine's stock? AdvisorShares Psychedelics ETF holds 112,693 shares of CMND stock, representing 1.94% of its portfolio. When did Clearmind Medicine's stock split? Clearmind Medicine shares reverse split on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMND) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.